Apr 4 |
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
|
Mar 27 |
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
|
Mar 25 |
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
|
Mar 8 |
Allarity Therapeutics GAAP EPS of -$10.26
|
Mar 8 |
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
|
Feb 28 |
Allarity Therapeutics to Present at Biomarkers 2024
|
Dec 12 |
Allarity Therapeutics appoints co-founder Thomas Jensen as interim CEO
|
Dec 12 |
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
|
Dec 7 |
ALLR: Stenoparib Clinical Update
|
Dec 5 |
Allarity stock soars 60% premarket on ovarian cancer therapy results
|